AstraZeneca’s heart drug wins approval in China
Hannah Blake
pharmaphorum
AstraZeneca’s new heart drug, Brilinta, has been approved by China’s State Food and Drug Administration, who has issued a drug import license for the product. This means Brilinta (ticagrelor) will now be available for treating patients with acute coronary syndrome in China.
Brilinta has already been proved better than the cheaper generic version, Plavix (clopidogrel), in preventing the recurrence of heart attacks in several studies. Plavix is marketed by Bristol-Myers Squibb and Sanofi.
While the drug hasn’t performed as well as originally hoped, China is an increasingly important market for AstraZeneca and so this recent approval may help to improve sales.
 ,
 ,
Related news:
AstraZeneca heart drug wins approval in China (Reuters)
AZ wins Chinese nod for lagging bloodthinner Brilinta (FiercePharma)
